The addition of a reputable institution like Banner MD Anderson Cancer Center as a clinical trial site can significantly enhance Phio Pharmaceuticals' ability to conduct its research effectively. This expansion is likely to improve patient recruitment rates, potentially accelerating the timeline for ongoing studies. Such developments are generally viewed positively by investors, as they can lead to faster progress in drug development and, ultimately, quicker paths to market and revenue generation.